What is the 13F Pro Quality Score for GNLX?

13F Pro ranks GENELUX Corp (GNLX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GNLX's current score at https://13fpro.ai/research/GNLX (free sign-up required for the full ranking).

Where does 13F Pro source GNLX data?

All GENELUX Corp fundamentals and ownership data come directly from SEC EDGAR. GENELUX Corp files with the SEC under CIK 1231457. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GNLX in?

GENELUX Corp (GNLX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GNLX research updated on 13F Pro?

GNLX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

GENELUX Corp(GNLX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1231457 GNLX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $11.1M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

GNLX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for GENELUX Corp (GNLX), a Healthcare sector company. GNLX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $11.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), GENELUX Corp reports net income of $-8.9M, free cash flow of $-7.0M. Top institutional holders of GNLX by reported 13-F value include WOODWARD DIVERSIFIED CAPITAL,, VANGUARD CAPITAL MANAGEMENT, Bleichroeder, based on the most recent SEC filings. GNLX trades on the Nasdaq exchange and files with the SEC under CIK 1231457. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GNLX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GENELUX Corp directly from SEC EDGAR.

Net Income

Q1 2026

$-8.9M

Free Cash Flow

Q1 2026

$-7.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+0.0% YoY

$8.0KFY 2025

FY21 —FY23 $170.0KFY24 $8.0KFY25 $8.0K

Net Income

-7.6% YoY

$-32.1MFY 2025

FY21 —FY23 $-28.3MFY24 $-29.9MFY25 $-32.1M

Operating Income

-4.8% YoY

$-33.2MFY 2025

FY21 —FY23 $-24.2MFY24 $-31.7MFY25 $-33.2M

EPS (Diluted)

+9.5% YoY

$-0.86FY 2025

FY21 —FY23 $-1.16FY24 $-0.95FY25 $-0.86

Total Assets

-45.2% YoY

$19.0MFY 2025

FY21 —FY23 $27.9MFY24 $34.7MFY25 $19.0M

Total Debt

—FY 2025

FY21 —FY23 $900.0KFY24 —FY25 —

Op. Cash Flow

-19.0% YoY

$-25.3MFY 2025

FY21 —FY23 $-20.3MFY24 $-21.2MFY25 $-25.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2021
Revenue	$8.0K +0.0%	$8.0K -95.3%	$170.0K	—
Net Income	$-32.1M -7.6%	$-29.9M -5.6%	$-28.3M	—
Operating Income	$-33.2M -4.8%	$-31.7M -31.2%	$-24.2M	—
EPS (Diluted)	$-0.86 +9.5%	$-0.95 +18.1%	$-1.16	—
Total Assets	$19.0M -45.2%	$34.7M +24.5%	$27.9M	—
Total Debt	—	—	$900.0K	—
Operating Cash Flow	$-25.3M -19.0%	$-21.2M -4.7%	$-20.3M	—

AI Insight: GNLX Financial Trends

GENELUX burns through $66M equity over seven quarters with zero revenue and persistent $6-9M quarterly losses.

• Revenue remained at $0M across all eight quarters from Q2 2024 through Q1 2026.

• Net losses consistently ranged $6-9M per quarter with no improvement trend over two years.

• Equity declined from $38M in Q2 2024 to $12M in Q4 2025, a 68% reduction.

• Equity rebounded from $12M in Q4 2025 to $23M in Q1 2026, suggesting capital raise.

⚠ Burn rate averaging $7M per quarter threatens runway despite recent equity increase to $23M.

⚠ Operating cash flow consistently negative $4-7M quarterly with no revenue generation pathway visible.

AI Insight: GNLX Ratio Trends

GENELUX continues burning cash with ROE deteriorating from -69.8% in Q2 2024 to -155.8% in Q1 2026, reflecting persistent losses in this early-stage biotech.

• ROE worsened from -69.8% in Q2 2024 to -155.8% in Q1 2026, indicating deepening losses relative to equity.

• ROA declined from -58.2% in Q2 2024 to -92.5% in Q2 2025, showing deteriorating asset utilization.

• ROIC dropped from -73.2% in Q2 2024 to -83.9% in Q3 2024 before data gaps emerged.

⚠ Increasing data gaps across profitability metrics in recent quarters may signal reporting complexities or structural changes.

⚠ Debt-to-equity ratio of 0.03 in Q4 2024 shows minimal leverage, but cash burn trajectory remains critical.

Get alerted when GNLX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GENELUX Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GNLX

WOODWARD DIVERSIFIED CAPITAL, LLC
$5.9M2,117,183 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.1M1,695,480 sh
Bleichroeder LP
$3.3M1,380,666 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.1M453,761 sh
BlackRock, Inc.
$982.2K405,872 sh
BANK OF AMERICA CORP /DE/
$783.8K323,865 sh
FLPUTNAM INVESTMENT MANAGEMENT CO
$679.8K280,904 sh
VANGUARD FIDUCIARY TRUST CO
$608.9K251,610 sh
CM Management, LLC
$605.0K250,000 sh
NORTHERN TRUST CORP
$398.0K164,456 sh

Fund	Value	Shares
WOODWARD DIVERSIFIED CAPITAL, LLC	$5.9M	2,117,183
VANGUARD CAPITAL MANAGEMENT LLC	$4.1M	1,695,480
Bleichroeder LP	$3.3M	1,380,666
GEODE CAPITAL MANAGEMENT, LLC	$1.1M	453,761
BlackRock, Inc.	$982.2K	405,872
BANK OF AMERICA CORP /DE/	$783.8K	323,865
FLPUTNAM INVESTMENT MANAGEMENT CO	$679.8K	280,904
VANGUARD FIDUCIARY TRUST CO	$608.9K	251,610
CM Management, LLC	$605.0K	250,000
NORTHERN TRUST CORP	$398.0K	164,456

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GNLX on your watchlist

Track score changes the day GENELUX Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GNLX a good stock to buy?

13F Pro's AI-powered analysis of GENELUX Corp (GNLX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GNLX are available on the GNLX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GNLX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GNLX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GENELUX Corp's investment landscape.